Clinical trial design in haemophilia

Haemophilia

Volumn 18, Issue SUPPL.4, 2012, Pages 18-23

  Dimichele, D M ^a   Blanchette, V ^b   Berntorp, E ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Clinical trials; Definitions; Haemophilia A; Haemophilia B; Health technology assessment; Observational studies

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; FUNDING; HEALTH CARE COST; HEMOPHILIA A; HEMOPHILIA B; HUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; STUDY DESIGN;

CLINICAL TRIALS AS TOPIC; COAGULANTS; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INTERNATIONAL COOPERATION; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84862889106     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02824.x     Document Type: Article

References (12)

1. National Research Council. Small Clinical Trials: Issues and Challenges. Washington, DC: The National Academies Press, 2001, Available at Accessed 20 January 2012.
2. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Chichester, England: John Wiley and Sons, 2004.
3. Chow SC, Chang M. Adaptive Design Methods in Clinical Trials. Second Edition. Boca Raton: Chapman & Hall, CRC, 2007.
4. White GC II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
5. World Federation of Hemophilia. Guidelines for the Management of Hemophilia 2005. Available at Accessed 2 February 2012.
6. Donadel-Claeyssens S. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006; 12: 124-7.
7. Ota S, McLimont M, Carcao MD et al. Definitions for haemophilia prophylaxis and its outcomes: the Canadian consensus study. Haemophilia 2007; 13: 12-20.
8. Berntorp E, Astermark J, Bjorkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9(Suppl. 1): 1-4.
9. International Network of Agencies for Health Technology Assessment HTA resources. Available at Accessed 13 January 2012.
10. Treatment of hemophilia and von Willebrand disease. Available at Accessed 13 January 2012.
11. Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol 2012 Apr; 88(4): 329-35.
12. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.